

TARGETED GENETICS CORP /WA/

Form 8-K/A

January 19, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K/A  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

**August 22, 2005**

**Targeted Genetics Corporation**

(Exact name of registrant as specified in its charter)

**Washington**

(State or other jurisdiction of incorporation)

**0-23930**

(Commission File Number)

**91-1549568**

(IRS Employer Identification No.)

**1100 Olive Way, Suite 100, Seattle, Washington**

(Address of principal executive offices)

**98101**

(Zip Code)

Registrant's telephone number, including area code

**(206) 623-7612**

**Not Applicable**

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

On August 22, 2005, Targeted Genetics Corporation filed a current report on Form 8-K announcing, among other things, the appointment of David J. Poston as Acting Chief Financial Officer.

On January 18, 2006, Targeted Genetics Corporation announced that Mr. Poston had been appointed Vice President, Finance, Chief Financial Officer and Treasurer. A press release announcing Mr. Poston's permanent appointment is attached as Exhibit 99.1 to this amended current report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits

Exhibits:	Description of Document
99.1	Press Release dated January 18, 2006

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Targeted Genetics Corporation

By: /s/ H. Stewart Parker  
H. Stewart Parker  
President and Chief Executive Officer

Dated: January 19, 2006

3

---

EXHIBIT INDEX

Exhibits:	Description of Document
99.1	Press Release dated January 18, 2006